HAE
Haemonetics Corp/Mass
NYSE · Health Care
$59.34
-5.68 (-8.74%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.26B | 1.13B | 2.16B | 2.17B | 1.94B |
| Net Income | 154.72M | 125.37M | 150.68M | 171.22M | 125.72M |
| EPS | — | — | — | — | — |
| Profit Margin | 12.3% | 11.7% | 7.0% | 7.9% | 6.5% |
| Rev Growth | +11.1% | +11.1% | -8.2% | +24.6% | +5.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 831.54M | 831.54M | 735.95M | 666.77M | 805.22M |
| Total Equity | 557.30M | 557.30M | 1.59B | 1.73B | 1.53B |
| D/E Ratio | 1.49 | 1.49 | 0.46 | 0.39 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 249.21M | 213.15M | 285.55M | 302.84M | 250.08M |
| Free Cash Flow | — | — | 149.87M | 163.13M | 182.49M |